A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy.
Bordoloi D, Bhojnagarwala PS, Perales-Puchalt A, Kulkarni AJ, Zhu X, Liaw K, O'Connell RP, Park DH, Kulp DW, Zhang R, Weiner DB. A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy. JCI Insight. 2022 11 22; 7(22).